Carlos L. Arteaga

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

Gabriel N. Hortobágyi, Salomon M. Stemmer, Howard A. Burris et al. · New England Journal of Medicine · 2016 · 2K citations · Full text

Medicine, Oncology, Pharmacology +17

Transforming Growth Factor-β1 Mediates Epithelial to Mesenchymal Transdifferentiation through a RhoA-dependent Mechanism

Neil A. Bhowmick, Mayshan Ghiassi, Andrei V. Bakin et al. · Molecular Biology of the Cell · 2001 · 996 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +16

Phosphatidylinositol 3-Kinase Function Is Required for Transforming Growth Factor β-mediated Epithelial to Mesenchymal Transition and Cell Migration

Andrei V. Bakin, Anne K. Tomlinson, Neil A. Bhowmick et al. · Journal of Biological Chemistry · 2000 · 991 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +17

Measurement of muscle mass in humans: validity of the 24-hour urinary creatinine method

Carlos L. Arteaga, C McManus, Janet E. Smith et al. · American Journal of Clinical Nutrition · 1983 · 869 citations

Medicine, Nephrology, Physiology +13

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer

Gabriel N. Hortobágyi, Salomon M. Stemmer, H. A. Burris et al. · Annals of Oncology · 2018 · 868 citations · Full text

Medicine, Oncology, Pharmacology +17